ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Zydus announces Phase I trials of ZYIL1, oral small molecule NLRP3 inflammasome inhibitor
December 08, 2020NLRP3 inflammasomes lead to the onset and development of diseases like ARDS, auto-immune diseases, inflammatory diseases, CVDs, metabolic disorders, gastrointestinal diseases, renal diseases and CNS diseases. -
Zydus Cadila files IND application for ZYIL1, NLRP3 inflammasome inhibitor
November 05, 2020Zydus announced that it has filed the IND application of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate. Following up on its initiatives to fight COVID 19 with diagnostics, vaccines and therapeutics, the company is now focussing on ...
Pharma Sources Insight January 2025
